Translation of "Gefäßverschlüsse" in English

The risk of vascular occlusive events is likely to be dose-related.

Venous occlusive reactions (treatment-emergent frequencies) occurred in 5.0% of patients.

The invention relates to a polymer compound for the production of sealing elements for vessel or container closures.

Arterial, as well as venous occlusive diseases have been associated with homocysteinemia.

It is still another objective of the invention to define corresponding container closures.

Long-term consequences of such circulatory disorders include vessel occlusions, vascular inflammations and calcifications of the arteries.

However, these visual field defects were not explained by detectable retinal artery occlusions.

A stabilisation of the thrombus might occur, resulting in increased risk of vessel occlusions.

Moreover, the invention encompasses the use of particularly suitable polymer compositions for the production of such vessel closures.

Stents are mainly used to prevent acute blood vessel closures or reforming of a stenosis after PTCA treatments.

A statistically correlation between increased anticardiodiolipin IgG-antibodies and retinal venous occlusion was found.

Serious vascular occlusion has occurred in patients treated with Iclusig, including cardiovascular, cerebrovascular and peripheral vascular events, and venous thrombotic events.

Further non-clinical studies will be conducted with the aim to further characterise the potential mechanisms for vascular occlusive events with ponatinib treatment.

The overall safety profile for ponatinib is generally consistent with that considered at the time of marketing authorisation, with the notable addition of the risk of vascular occlusive events.

This raises the question of whether similar outcomes in terms of efficacy could be achieved with lower (starting and/or maintenance) doses, which are expected to reduce the risk of vascular occlusive events.

Elevation of FVIII levels following administration, in particular with existing cardiovascular risk factors, might put a patient into the same risk for vessel closure or myocardial infarction as for the non-haemophilic population.

Elevation of FVIII levels following administration, in particular in those with existing cardiovascular risk factors, might cause a patient to have the same risk for vessel closure or myocardial infarction as for the non-haemophilic population.

Elevation of factor VIII levels following administration, in particular in those with existing cardiovascular risk factors, might cause a patient to have the same risk for vessel closure or myocardial infarction as for the non-haemophilic population.

In view of the high risk for vascular occlusive events, the PRAC considered that it should be made clear in the product information that ponatinib should be discontinued in patients who do not respond to treatment (no haematologic response by 3 months).

The possible role of anti-platelet, anti-coagulant or lipid lowering drugs in reducing the risk of vascular occlusive events remains uncertain.

For the indications “ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin” and “acute retinopathies of vascular origin” the CHMP noted that positive clinical results (in particular regarding the progression of visual acuity) were described mainly in one open long-term study in the context of an ambulatory ophthalmological practice that involved 213 patients with heterogeneous pathologies (e.g. retina degeneration, inflammatory diseases of the retina and of the optic nerve, venous and arterial vessels occlusions, glaucoma, etc) (Hasslinger, 1986).